BaCKGroUNd: Lymph node metastasis is an important indicator of oncologic outcome for patients with rectal cancer. Identifying predictive biomarkers of lymph node metastasis could therefore be clinically useful.
P reoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME) is the current standard of care for locally advanced rectal cancer. 1 This treatment provides excellent local tumor control and long-term survival. 2, 3 However, TME is a formidable operation associated with some mortality, significant morbidity, and long-lasting sequelae that permanently impair quality of life. 4, 5 Patient response to CRT is also variable. Whereas a proportion of patients with rectal cancer treated with CRT have no detectable cancer cells in the bowel wall or mesorectal lymph nodes and achieve a pathologic complete response (pCR), other patients have only a partial response and have persistent cancer cells in their surgical specimens.
It is well established that patients with a pCR have better oncologic outcomes in comparison with non-pCR patients, with lower local recurrence, less distant metastasis, and improved overall survival. 2, 3 However, there is currently no accurate way to predict the presence of residual cancer cells in the mesorectal lymph nodes before surgery. 6 Histopathological analysis following TME remains the most reliable way to identify patients with tumor deposits in the mesorectal lymph nodes who are at risk of metastatic disease.
The human genome is a patchwork of DNA segments with a high degree of variability in copy number, order, and orientation between individuals and populations. Studies have shown that of the various structural variations that occur, the physical gain or loss of DNA segments from chromosomes, known as copy number alterations (CNAs), is a common occurrence in many genetic diseases, 7 and many studies have examined the role that these DNA additions (gains) or deletions (losses) play in disease. 8 The presence of DNA CNAs is also a cardinal feature of cancer, characterized by the gain and loss of entire chromosomes or chromosomal segments (known as aneuploidy). This includes colorectal cancer. 9, 10 Gains and losses of chromosomal segments lead to changes of gene expression in oncogenes and tumor suppressor genes that are important for the progression of colorectal cancer.
The hybridization of tumor DNA to normal metaphase chromosomes, a technique known as comparative genomic hybridization (CGH), allows for the simultaneous screening and mapping of gains and losses of specific chromosomal segments. 11, 12 New high-throughput approaches, such as array-based comparative genomic hybridization (aCGH) using oligonucleotides, allow genome-wide detection of chromosomal CNAs at a higher resolution in comparison with metaphase-based CGH. Oligonucleotide aCGH is therefore one of the preferred methods to characterize the degree of chromosomal complexity in cancer.
Emerging evidence suggests that specific CNAs are associated with distant metastasis in advanced colorectal cancer, [12] [13] [14] but no studies have examined CNAs and persistent lymph node metastasis specifically in rectal cancer. Given that lymph node metastasis is a critical indicator of clinical outcome, it would be clinically useful if high-risk patients could be accurately identified before surgery because this may help direct therapy.
We used high-density whole genome oligonucleotide aCGH to identify CNAs in patients with locally advanced rectal cancer to determine whether a specific CNA profile associates with persistent lymph node metastasis. Here, we present the CNA profiles for 95 patients with rectal cancer treated with CRT and TME, compare CNAs between lymph node-positive and -negative patients, and describe the value of this molecular approach for predicting persistent lymph node metastasis in patients with rectal cancer.
MatErialS aNd MEtHodS

Patients
This study included patients with clinical stage II (cT3-4, cN0) or stage III (any cT, cN1-2) invasive adenocarcinoma of the rectum with a distal tumor border within 12 cm of the anal verge, as measured on rigid proctoscopic examination, who were enrolled in the Timing of Rectal Cancer Response to Chemoradiation study, a multi-institutional clinical trial investigating the effect of increasing the CRT-to-surgery interval, and adding chemotherapy, modified FOLFOx-6 (mFOLFOx-6) during the waiting period (www.ClinicalTrials.gov identifier NCT00335816). This trial was designed in a series of sequential phase II trials or study groups (SGs), each with a progressively longer CRT-to-surgery interval and increasing cycles of preoperative mFOLFOx-6. This study was approved by an institutional review board at each participating institution, and a central institutional review board, and informed written consent was obtained from each patient before enrollment in the trial. Patients included in the present study were pooled from SG1 (n  43) and SG2 (n  52). Further details of patient eligibility for this trial are presented elsewhere. 15 
treatment Protocol
Patients in both groups were treated with CRT: 5-fluorouracil, and a total of 50.4 Gy of radiation as described previously. 15 Patients in SG1 underwent TME an average of 6 weeks after completing CRT (standard of care). After CRT, patients in SG2 with no evidence of stable disease received 2 cycles of additional chemotherapy (mFOLFOx-6) as described previously. 15 Patients in SG2 underwent TME an average of 11 weeks after completing CRT. The clinical outcomes for these patients are presented elsewhere. 15 tumor response and lymph Node Status Patients were assessed for tumor response (pCR versus non-pCR) and lymph node status (ypN1-2 versus ypN0) after TME. pCR was defined as the complete absence of tumor cells from the bowel wall and mesorectal lymph nodes. An average of 14 lymph nodes was collected from each patient. Tumor response and lymph node status were evaluated by 2 independent pathologists according to the recommendations of the American Joint Committee of Cancer.
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Sample Preparation, Whole Genome amplification, and oligonucleotide aCGH Tumor DNA from each patient was obtained from pretreatment biopsy tissue, and control DNA was obtained following treatment from paired normal surgical tissue from the proximal resection margin. To extract DNA, 10 to 20 slides per patient sample from formalin-fixed paraffinembedded tumor biopsy and normal tissue were deparaffinized, hydrated, and stained with 0.2% methylene blue. A 27.5-gauge needle was then used to manually microdissect cells under inverted microscopy. This method ensured that the purity of the tumor cells in each extracted DNA specimen was at least 85%. DNA was quantified by measuring absorbance, and 100 to 200 ng of DNA was amplified by use of the GenomePlex Complete Whole Genome Amplification (WGA)-2 kit (Sigma Corp., Cream Ridge, NJ). WGA-DNA was purified with the GenElute PCR Clean-up kit (Sigma Corp., Cream Ridge, NJ) and quantified. DNA quality was determined by running 2 µL of WGA-DNA on a 2% agarose gel. If the size of any DNA amplicon was less than 200 base pairs in size (a marker of poor quality), the sample was removed from the study because it was deemed unsuitable for aCGH. Only samples 200 base pairs in size were included in the current study.
The Agilent microarray platform was used for oligonucleotide aCGH (Human Genomic CGH 244A Microarrays), with 8.9 kb overall median probe-spacing covering more than 236,000 coding and noncoding human DNA sequences. aCGH assays were conducted according to manufacturer's instructions (Agilent Corp., Santa Clara, CA). In brief, for each sample, 2 µg of WGA-DNA was labeled with the nonenzymatic universal Linkage System (uLS). Equal amounts of tumor biopsy and paired normal surgical specimen DNA were labeled with uLS-Cy5 and uLS-Cy3. The labeled samples were purified by use of Agilent-KREApure columns, and then combined with the hybridization mixture in a SureHyb chamber. Hybridization of arrays was performed at 65°C for 40 hours. Arrays were then washed in wash buffer-1 and wash buffer-2.
Scanning and image analysis were performed on an Agilent scanner. Agilent Feature Extraction Software (v.9.5) was used for data extraction from raw microarray image files.
Statistical analysis
Patient Characteristics. To determine differences in clinicopathological features between cN1-2 and cN0 patients, and between ypN1-2 and ypN0 patients, Student t test was used to compare means of continuous variables, and the 2-sided Fisher exact test or the Fisher-Freeman-Halton exact test with the use of Monte Carlo sampling was chosen for categorical variables.
Characterizing Chromosomal CNas. Nexus copy number software (v.5.0) (BioDiscovery Inc, El Segundo, CA) was used to identify chromosomal CNAs by using the rank segmentation algorithm, a modified version of the circular binary segmentation algorithm, as described previously. 17 Copy number alterations were determined for each sample, and the fraction of genome alteration (FGA) was calculated to reflect the degree of genomic instability. The FGA was determined by dividing the overall altered segment size by the genome size with the use of the National Center for Biotechnology Information hg18 database (Build 36.1) comprising 3,080,436,051 base pairs.
identifying CNa Signatures. unsupervised hierarchical cluster analysis was used to analyze the distribution of whole genome CNA profiles. The CNAs that differed between cN1-2 and cN0 patients, and between ypN1-2 and ypN0 patients were identified by use of Nexus copy number software (v.5.0) (BioDiscovery Inc, El Segundo, CA) (p  0.05, differential threshold 25%). To assess CNA differences between cN1-2 and cN0 patients, and between ypN1-2 and ypN0 patients, the 2-sided Fisher exact test was used and Q-bound was used to correct for multiple testing by performing false discovery rate (FDR) analysis, defined as the proportion of false positives among all positives. 18, 19 A Q-bound score of 0.05 was considered statistically significant.
19
identification of Functionally relevant Genes in ypN1-2 and ypN0 patients. The genes within CNA regions that differed between ypN1-2 and ypN0 patients were identified by using Fisher's Exact test (p value  0.05, differential threshold 25%), and potential gene candidates for human cancer were prioritized among the genes relevant to persistent lymph node metastasis by using biomarker filter analysis (Ingenuity Systems, Inc, Redwood City, CA).
Predicting Persistent lymph Node Metastases after Neoadjuvant Crt. Predictive biomarkers for persistent lymph node metastasis were derived by use of a combination of methods including feature (candidate biomarker) selection, classification model fitting, and cross-validation, as described previously. 20, 21 Differential features were selected from all probes on the aCGH array based on 2 criteria: FDR, the adjusted p values by use of the Benjamini and Hochberg method 18 based on the p values of the Student t test between ypN1-2 and ypN0 patients, and probe-signal fold-change between ypN1-2 and ypN0 patients. The features were fed into the linear-kernel Support Vector Machine (SVM) classifier to train the classification model based on the selected features. 22 Leave-one-out crossvalidation was performed to evaluate the classification performance on test samples. ROCR package 23 was used to calculate performance measures such as sensitivity, specificity, and positive and negative predictive values, and to plot the performance measures by use of the receiver operating characteristic (ROC) curve. The area under the ROC curve was calculated to quantitatively summarize the performance of the model. The final predictive model contained 65 features with the use of the following feature selection cutoffs: FDR threshold 0.15; absolute log 2 fold-change 0.55. (Table 1) and pathologic lymph node status (Table 2) . Before treatment, 75% of patients were Table 1) . After CRT, 25 of 95 (26%) patients were ypN1-2 ( Table 2) ; 11 of 43 patients (26%) were in SG1, and 14 of 52 patients (27%) were in SG2. The total number of lymph nodes examined for the entire patient cohort differed significantly between ypN1-2 and ypN0 patients, with more lymph nodes retrieved in the ypN1-2 group (p  0.006) ( Table 2) . Twenty-seven of 95 (28%) patients were ypT0, and only 2 of these patients were ypN1-2. The remaining 25 ypT0 patients were ypN0, indicating that persistent lymph node metastasis significantly associates with ypT1-4 after CRT (p  0.009).
Chromosomal CNa Gains and losses overall and Stratified by Pretreatment Clinical Stage and lymph Node Status after Crt
We found no difference in copy number gains and losses between cN1-2 and cN0 patients (data not shown). The mean number of copy number gains and losses overall and stratified by lymph node status after CRT are presented in Table 3 . Patients who were ypN1-2 had a higher number of total gains and losses, a higher number of single-copy gains and losses, a higher number of high copy gains, a higher FGA, and a lower number of high copy losses in comparison with ypN0 patients. These differences showed a strong trend toward statistical significance.
Specific Chromosomal CNas overall and Stratified by Pretreatment Clinical Stage and lymph Node Status after Crt
In the entire patient cohort, overall copy number gains most frequently affected chromosomal regions 20q11.21-q13.33 (68%), 13q11-34 (55%), 7p22.3-p22.2 (36%), and 8q23.3-q24.3 (36%), whereas losses were most frequently observed in chromosomal regions 18q11.32-q23 (60%), 17p13.3-q11.1 (39%), 10q23.1 (38%), and 4q32.1-q32.3 (37%) (Fig. 1A) .
A total of 207 chromosomal regions were found to be different between cN1-2 and cN0 patients, but when the p value was corrected by multiple testing (FDR), none of the differences reached statistical significance (Supplementary Table 1 , http://links.lww.com/DCR/A79).
Chromosomal regions associated with persistent lymph node metastasis were identified by comparing Values shown are mean 6 standard deviation. CNA  copy number alteration; FGA  fraction of genomic alteration; ypN1-2  pathologic lymph node positive after chemoradiation; ypN0  pathologic lymph node negative after chemoradiation.
FIGURE 1. Copy number alterations detected by aCGH (A) overall and (B)
stratified by lymph node status (ypN1-2, n  25 versus ypN0, n  70). Loss of chromosome 4 depicted in the dashed box was found to be the most significantly different CNA region between lymph node-positive (ypN1-2) and lymph node-negative (ypN0) patients. aCGH  array-based comparative genomic hybridization; CNA  copy number alterations. Sample identification: red  loss; green  gain. Y  X  22  21  20  19  18  17  16  15  14  13  12  11  10  9  8  7  6  5  4 the CNA profiles of ypN1-2 and ypN0 patients (Fig. 1) . A total of 1023 chromosomal regions were found to be different (gained or lost) between ypN1-2 and ypN0 patients with a minimal differential threshold of 25% and a p value of 0.05 (Supplementary Table 2 , http://links. lww.com/DCR/A79). When p values were corrected for multiple testing and a Q-bound of 0.05 was applied, loss of 270 regions remained associated with ypN1-2 disease (Supplementary Table 3 , http://links.lww.com/DCR/ A79). Notably, 248 of the 270 (92%) differential regions associated with persistent lymph node metastasis were in chromosome 4, and more than half of these (135 of 248 regions (54%) on chromosome 4) were found to be the most significantly different between ypN1-2 and ypN0 patients.
Given the extensive sequence overlap provided by high-density arrays, most of the differential regions were close to one another (with an internal distance of 1 megabase) and were combined to form a number of large consecutive sequences. After combining the consecutive CNAs, loss of 28 chromosomal regions in chromosomes 1, 2, 4, 6, 10, 11, and 14 occurred significantly more frequently in ypN1-2 patients than in ypN0 patients ( Table 4 ).
Genes that differed Between ypN1-2 and ypN0 Patients
The chromosomal regions that differed between ypN1-2 and ypN0 patients contain 342 genes (Supplementary Table 3, http://links.lww.com/DCR/A79). To identify genes that may play a role in persistent lymph node metastasis, we used biomarker filter analysis (Ingenuity Systems, Inc, Redwood City, CA) to search for the genes relevant to persistent lymph node metastasis. We identified 22 of 342 potential biomarker candidates associated with cancer prognosis, disease progression, therapeutic efficacy, response to therapy, and diagnosis ( Table 5 ). All of these genes were lost more frequently in ypN1-2 patients than in ypN0 patients.
Predicting Persistent lymph Node Metastases after Neoadjuvant Crt
To determine how accurately oligonucleotide aCGH can predict persistent lymph node metastasis in patients with rectal cancer, a biomarker model was built with the use of SVM. Sixty-five probes were selected by use of FDR and fold-change cutoffs (FDR threshold 0.15; absolute log 2 fold-change 0.55) (Supplementary Table 4 , http:// links.lww.com/DCR/A79). With the use of leave-one-out cross-validation, aCGH predicted persistent lymph node metastasis with a sensitivity of 68%, specificity of 93%, positive predictive value of 77%, and negative predictive value of 89%. Lymph node status (ypN1-2 or ypN0) was predicted accurately in 82 of 95 patients (86%) with this model (Fig. 2) , and the performance of the model was plotted as an ROC curve with an area under the ROC curve value of 0.91.
diSCUSSioN
In our study we showed that CNAs detected by oligonucleotide aCGH may help identify patients with rectal cancer who are likely to have persistent lymph node metastasis after CRT. We found that ypN1-2 patients had more overall copy number gains and losses in comparison with ypN0 CNA  Copy number alteration; ypN1-2  pathologic lymph node positive after chemoradiation; ypN0  pathologic lymph node negative after chemoradiation. *A Q-bound score of 0.05 was considered statistically significant.
patients, and that losses of 28 chromosomal regions, predominantly in chromosomes 4, 10, 11, 14, and 6, occurred significantly more frequently in ypN1-2 patients than in ypN0 patients. We also found that persistent lymph node metastasis was significantly associated with tumor response after CRT, and that patients with ypT0 tumors were significantly less likely to have persistent lymph node metastasis in comparison with ypT1-4 tumors. Finally, we built a persistent lymph node metastasis prediction model that contained 65 probes and predicted ypN1-2 status with a high degree of accuracy. Conversely, we found no correlation between pretreatment clinical stage and pathologic lymph node stage; and there were no CNA differences between clinical node positive and negative patients. This likely reflects the inaccuracy of current clinical staging methods such as imaging technology in identifying nodal metastasis.
Only one previous study has focused on identifying a specific correlation between CNAs in primary tumors with lymph node metastasis in colorectal cancer. 24 In this study, the CNA profiles of 50 patients with colorectal cancer were determined, and the authors found that gain of chromosome 8q23-24 may be predictive of lymph node metastasis. Gain of chromosome 8q24.3 also occurred significantly more frequently in ypN1-2 versus ypN0 patients in our study (p  0.02) (Supplementary Table 2 , http:// links.lww.com/DCR/A79). However, when the data were corrected for FDR (Q-bound), this CNA was no longer significant (Q-bound  0.44). Additional independent studies have also suggested that 8q24.3 may play a role in distant metastasis. 14 Therefore, gain of this chromosomal region may indeed be an indicator of persistent lymph node metastasis in rectal cancer after CRT, and the possible false negative we observed may be due to our statistical threshold (Q-bound) being set at a more stringent level (0.05) to correct for multiple testing.
Of the 28 CNAs significantly associated with persistent lymph node metastasis in our study, more than half (61%) were located in chromosome 4. Other studies have also shown an association between loss of chromosome 4p or 4q and metastasis in colorectal cancer. [25] [26] [27] Diep et al 25 analyzed genome-wide CNAs in 373 colorectal tumors and 102 liver metastases, and showed that loss of chromosome 4p and 4q were significantly associated with disease progression. Arribas et al 26 showed that loss of heterozygosity of 4p14-16 was indicative of a shorter disease-free survival period in 143 patients with colorectal cancer. Bardi et al 27 performed cytogenetic analysis of 150 primary colorectal cancers and demonstrated that loss of chromosome 4 was significantly correlated with shorter disease-free survival. Our data are largely consistent with previous studies and suggest that loss of chromosome 4 may play an important role in tumor progression, persistent lymph node metastasis, and decreased overall survival. Thus, screening for this CNA with the use of aCGH in patients with rectal cancer may help identify at-risk patients and direct appropriate treatment.
Our predictive model comprises 65 probes that contain 34 genes. There is substantial evidence suggesting that genomic alterations can result in corresponding gene expression changes in colorectal cancer, as shown by integrating gene expression and DNA copy number profiles. So it is possible that one or more of the 34 genes we identified may be important in lymph node metastasis in rectal cancer. However, it will be necessary to examine these individual genes in the future to determine whether their expression is indeed altered and to establish their clinical significance, if any.
Although we showed aCGH to be an effective predictor of persistent lymph node metastasis in rectal cancer, it is notable that we found tumor response to CRT to be the best predictor of persistent lymph node metastasis. In our patient cohort, all but 2 ypT0 patients (93%) were ypN0, suggesting that patients with excellent tumor response in the bowel wall are highly unlikely to be ypN1-2.
A number of limitations to our study deserve mention. Although our aCGH analysis was based on the largest rectal cancer cohort reported thus far, the patient group was not completely homogeneous; there were 2 treatment arms in our study, and although all patients received preoperative CRT, some patients also received additional chemotherapy that may have influenced their clinical outcome. In addition, although we performed rigorous statistically sound internal validation, external validation of our predictive model will be important to further corroborate our findings. Finally, we compared DNA from pretreatment tumor to posttreatment DNA from normal surgical margins. This raises the issue of whether the posttreatment control tissue may have been affected by the CRT and additional neoadjuvant chemotherapy. However, the control tissue was obtained from the proximal resection margin, which is usually outside the radiation field, and there are no data indicating that CNAs arise following chemotherapy treatment of normal tissue. Furthermore, we have recently shown that mutations in KRAS and TP53, 2 genes that play a role in the pathogenesis of rectal cancer, remain largely unchanged after CRT in patients with rectal cancer. 28 
CoNClUSioN
We showed that specific CNAs are significantly associated with persistent lymph node metastasis following CRT in locally advanced rectal cancer, in particular, loss of chromosome 4. These findings are clinically relevant and support the use of aCGH to identify those patients who are more likely to have persistent lymph node metastasis and to direct them to receive appropriate systemic therapy. This approach may also help identify those patients who are highly unlikely to have lymph node metastasis and who may ultimately benefit from an organ preservation approach.
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